Learning Objectives:


  • Review the rationale for assessing measurable residual disease (MRD) in multiple myeloma (MM).
  • Learn about whether MRD negativity can be used as a surrogate endpoint in MM.
  • Learn how multimodal MRD assessments can guide decision making in MM.
Session date: 
06/17/2024 - 12:00pm to 1:00pm CDT
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation

Please login or create an account to proceed.
Speaker Name: 
Ben Derman, MD